KALV:NASDAQKalVista Pharmaceuticals, Inc. Analysis
Data as of 2026-05-26 - not real-time
$26.79
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
KalVista’s price is riding a strong technical backdrop – the 20‑day SMA (~26.0) sits above the 50‑day (~21.7) and 200‑day (~16.0) averages, signalling a bullish trend, yet the RSI of 74.6 flags an overbought condition and the MACD histogram has turned negative, hinting at short‑term weakness.
The stock trades near its recent resistance (~26.85) with a support zone around 18.94, and the market sentiment is at “Extreme Greed” (91.8 on the Fear & Greed Index), which could fuel further upside but also increase volatility.
Fundamentally, the company carries a forward PE of ~22.4 versus an industry average of 27.6, suggesting a modest valuation advantage, yet it reports negative operating margins, cash burn and a recent insider sale by the CMO, while regulatory risk remains high for its biotech pipeline.
The stock trades near its recent resistance (~26.85) with a support zone around 18.94, and the market sentiment is at “Extreme Greed” (91.8 on the Fear & Greed Index), which could fuel further upside but also increase volatility.
Fundamentally, the company carries a forward PE of ~22.4 versus an industry average of 27.6, suggesting a modest valuation advantage, yet it reports negative operating margins, cash burn and a recent insider sale by the CMO, while regulatory risk remains high for its biotech pipeline.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI in overbought territory
- Bearish MACD histogram
- Proximity to technical resistance
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Bullish SMA crossover confirming trend
- Forward PE below industry average
- Potential pipeline catalyst and cash runway
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- High cash‑burn and negative operating margins
- Regulatory approval uncertainty
- Valuation modestly attractive relative to peers
Key Metrics & Analysis
Financial Health
Profit Margin-118.74%
P/E Ratio22.4
P/B Ratio-505.5
Op. Cash Flow$-89319504
Industry P/E27.6
Technical Analysis
TrendBullish
RSI74.7
Support$18.94
Resistance$26.85
MA 20$25.98
MA 50$21.67
MA 200$16.00
MACDBearish
VolumeDecreasing
Fear & Greed Index91.8
Valuation
Target Price$28.60
Upside/Downside6.76%
GradeFair
TypeGrowth
Risk Assessment
Beta0.73
Volatility101.72%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.